Evidence map›Paper›PMID 31798276›Full record

ArticleWorld journal of gastroenterology2019

Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis

Jian Guo, Mu Wang, Jun-Ping Wang, Chang-Xin Wu

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Ubiquitin-conjugating Enzymes in Cancer.International journal of biological sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in genetics · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. RNA Sequencing Analysis of Gene Expression by Electroacupuncture in Guinea Pig Gallstone Models.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jian GuoInstitute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan 030006, Shanxi Province, China.
Mu WangDepartment of Neurology, Shanxi Provincial People's Hospital, the Affiliated People's Hospital of Shanxi Medical University, Taiyuan 030012, Shanxi Province, China.
Jun-Ping WangDepartment of Gastroenterology, Shanxi Provincial People's Hospital, the Affiliated People's Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Chang-Xin WuThe Institutes of Biomedical Sciences, Shanxi University, Taiyuan 03006, Shanxi Province, China.
Shanxi Medical University · CNShanxi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is now the most common primary liver malignancy worldwide, and multiple risk factors attribute to the occurrence and development of HCC. Recently, increasing studies suggest that ubiquitin-conjugating enzyme E2T (UBE2T) serves as a promising prognostic factor in human cancers, although the molecular mechanism of UBE2T in HCC remains unclear.

aimTo investigate the clinical relevance and role of UBE2T in HCC development.

methodsUBE2T expression in HCC tissues from the TCGA database and its association with patient survival were analyzed. A lentivirus-mediated strategy was used to knock down UBE2T in HCC cells. qRT-PCR and Western blot assays were performed to check the effect of UBE2T silencing in HCC cells. Cell growth

resultsUBE2T was overexpressed in HCC tissues compared with paired and non-paired normal tissues. High expression of UBE2T predicted a poor overall survival in HCC patients.

conclusionUBE2T plays an important role in cell cycle progression, apoptosis, and HCC development.

Indexed as

CarcinogenesisOncogenesApoptosisCarcinoma, HepatocellularCell CycleCell Line, TumorGene Knockdown TechniquesHumansLiver NeoplasmsUbiquitin-Conjugating EnzymesUBE2T protein, humanUbiquitin-Conjugating EnzymesApoptosisCell cycleHepatocellular carcinomaTumorigenesisUbiquitin-conjugating enzyme E2T

Identifiers

PMID31798276
PMCPMC6881511
OpenAlexW2989585224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.